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Abstract 
Background: To determine the current door-to-
needle time for the administration of fibrinolytics 
for acute myocardial infarction (AMI) in emergency 
room. 
Methods: In this cross sectional study  patients  
presenting  with acute myocardial infarction (AMI) 
were included. Time interval from patient’s 
presentation to administration of streptokinase to 
the patient, was calculated . The total door-to-needle 
time was calculated and patient demographics and 
presentation, physician’s experience, clinical 
symptomology and reasons for delays in 
thrombolytic administration were analysed. 
Results:  Sixty six patients, presented with AMI, 
were given streptokinase. Out of these, 6% received 
streptokinase within 15 minutes of arrival in 
emergency, 22.7%received streptokinase in 30 
minutes, 33.33% received thrombolytic agent in 45 
minutes, 27.27%  received thrombolytic therapy in 60 
minutes, and 10.7% received thrombolytic therapy in 
90 minutes. The mean door to needle time calculated 
was 44.8 minutes. Patients receiving reperfusion 
therapy within 30 minutes were 28.7%. 
Conclusion:  A significant number of patients 
were not thrombolysed within 30 minutes of 
presentation.The non-availability of senior doctors, 
difficulty in interpreting ECGs, atypical 
presentations and ER system delays, prolonged the 
door-to-needle time in this study. 
Key words: Door to needle time , Acute 
myocardial infarction, Streptokinase 
Introduction 
Ischaemic heart disease (IHD) is a major cause of 
mortality and morbidity worldwide, especially in 
industrialised countries.1 In keeping with international 
studies, mortality from IHD was higher in males than 
females.2 Myocardial infarction is the major cardiac 
emergency presented in Benazir Bhutto Hospital 
Rawalpindi. While primary prevention of IHD is 
considered the ideal, mortality and morbidity in 
patients presenting with acute myocardial infarction 
(AMI) can be reduced with early interventions such as 
fibrinolysis or percutaneous coronary intervention 
(PCI).3 Many studies have shown that early PCI is 
more advantageous in reducing mortality from re-
infarction and the need for a coronary artery bypass 
graft (CABG) than fibrinolytic drug therapy.4- 6  In 
Rawalpindi, PCI is limited to two tertiary hospitals, 
making fibrinolytic drug therapy the more accessible 
form of treatment for ST elevation myocardial 
infarction (STEMI) patients. 
In keeping with the mantra “Time is muscle”, early 
administration of fibrinolytic therapy preserves left 
ventricular function by increasing patency of occluded 
vessel and thus limiting infarct size.7, 8 Maximal benefit 
from fibrinolysis is seen when the fibrinolytic is given 
within the first hour of symptom onset.9, 10 Delaying 
fibrinolytic therapy by one hour increases the hazard 
ratio of death by 20%, (95% confidence interval (CI) 7 - 
88), and a delay of 30 minutes or more can reduce the 
average life expectancy by one year.11The period 
between the onset of symptoms to administration of 
fibrinolytic therapy can be divided as :1. Interval 
between onset of symptoms to seeking medical 
attention; 2. Period taken to transport patient to 
definitive care;3. Interval between arrival at hospital to 
initiation of fibrinolytic (door-to-needle time).The first 
two components can be improved by public education 
and developing efficient pre-hospital systems. For 
example, North Carolina has adopted a state wide 
STEMI referral strategy that advises paramedics to 
"bypass" local hospitals and transport STEMI patients 
directly to a PCI-capable hospital, even if a non-PCI-
capable hospital is closer.This results in shorter 
reperfusion times.12 But door-to-needle time is the one 
in-hospital factor that can be addressed by medical 
practitioners.The American Heart 
Association/American College of Cardiology 
(AHA/ACC) guidelines recommend a door-to-needle 
time of 30 minutes or less for administration of 
fibrinolytic for STEMI patients. 1.Compliance with this 
time period is considered a marker of quality of care. 14 
European Society of Cardiology recommends First 
Medical Contact time to ECG time of Less than 10 
minutes and also recommends door to needle time of 
less than 30 minutes.15 
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Patients and Methods 
This prospective study was conducted on  all patients 
who received thrombolytics for AMI in the Emergency 
of BBH from August 2016 to October 2016.All adult 
patients with acute ST segment elevation, new onset 
left bundle branch block (LBBB), or posterior infarct on 
electrocardiogram (ECG) meeting AHA/ACC criteria 
for thrombolysis, who received thrombolytics in the 
emergency BBH. Exclusion criteria was patients who 
received pre-hospital thrombolysis or those 
thrombolysed at other centres before referral; patients 
receiving thrombolytic therapy for conditions other 
than myocardial infarction e.g. pulmonary embolism. 
The quality of data collected was dependent on the 
availability and accuracy of the case notes. Incomplete 
documentation, and illegible and ambiguous notes 
were identified.Data  collated and analysed was 
patient demographics,pre-hospital ECG acquisition 
and presence or absence of attendants. Time intervals 
calculated were time of presentation to hospital (taken 
from Emergency slip) to time of ECG acquisition,time 
from ECG acquisition to actually commencing 
thrombolytics and the sum of the above time intervals 
constitutes the total door-to-needle time. 
 Simple descriptive statistics were used to describe the 
meantime to ECG, ECG to fibrinolytic, and total door-
to-needle times. Subgroup analysis was performed for 
determining prevalence of STEMI patients fibrinolysed 
based on gender and age group; and pre hospital ECG 
acquisition. The symptoms on presentation were also 
assessed. Typical symptoms were defined as an acute 
onset of chest pain with radiation to the left arm, neck 
or jaw with associated autonomic symptoms 
(sweating, nausea or vomiting).Ethics approval was 
granted by the Research Committee of Rawalpindi 
Medical University.  
Results 
Sixty six patients presented with AMI were given 
streptokinase. Out of these, 6% (n=4) of these patients 
received Streptokinase within 15 minutes of arrival in 
Emergency and 22.7% (n=15) of these patients received 
Streptokinase in 30 minutes (Table 1).. The Mean Door 
to Needle Time Calculated was 44.8 Minutes (Table 2). 
Patients receiving reperfusion therapy within 30 
minutes were 28.7%.  Majority (74%) had a typical 
presentation of AMI (Table 3) 
Table 1 : Door to needle time in minutes 
Door to needle time in minutes %(n) n=66 
Within 15 minutes of arrival 6% (n=4) 
16 - 30 minutes 22.7% (n=15) 
31 – 45 minutes 33.33% (n=22) 
46 – 60 minutes 27.27% (n=18) 
61 – 90 minutes & more 10.7% (n=7) 
Table 2: Mean time achieved for each interval in 
minutes 
Time Interval Mean time (minutes) 
  
Door to ECG 17.4 Minutes 
ECG to Thrombolysis   27.4 Minutes 
Door to needle time    44.8 Minutes 
Table 3: Demographic variables 
Variable No Percentag
e  
Sex 
Male 43 65.2 
Female 23 34.8 
Age (years) 
25-40 5 7 
41-60 37 56 
>60 24 37 
Pre-Hospital ECG Acquisition 
Pre-Hospital ECG  3 4.5 
Symptomology 
Typical 49 74 
Atypical 17 26 
 
Discussion 
The prognosis of acute myocardial infarction patients 
depends on timely administration of fibrinolytic 
therapy.9,10,35  American Heart Association and 
European Society of Cardiology recommends door to 
needle time of 30 minutes for fibrinolytic therapy.13,15 
But unfortunately these guidelines are not followed 
.Adherence to these guidelines has improved care of 
patients with AMI and is associated with significant 
reductions in in-hospital mortality rates.16,17,18,19 Timely 
diagnosis of ST‐segment elevation myocardial 
infarction (STEMI) in the emergency department (ED) 
is made solely by ECG. Obtaining this test within 10 
minutes of ED arrival is critical to achieving the best 
outcomes as recommended by ESC and AHA.A recent 
study published in Journal of American Heart 
Association in February 2017 evaluated performance 
of Emergency Department Screening Criteria for an 
Early ECG to Identify ST‐Segment Elevation 
Myocardial Infarction .They examined STEMI 
screening performance in 7 EDs, with the missed case 
rate (MCR) as their primary end point. The overall 
MCR for all 7 EDs was 12.8%. The lowest and highest 
MCRs were 3.4% and 32.6%, respectively. The mean 
difference in door‐to‐ECG times for captured and 
missed patients was 31 minutes, with a range of 14 to 
80 minutes of additional myocardial ischemia time for 
missed cases. The prevalence of primarily screened ED 
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STEMIs was 0.09%.The 29.2% difference in MCRs 
between the highest and lowest performing EDs 
demonstrates room for improving timely STEMI 
identification among primarily screened ED patients.20 
In a Canadian registry of 3,088 AMI patients in 2000–
2001, 63% of the patients failed to receive fibrinolytic 
therapy within 30 minutes of ED arrival.21  Another 
study done in Canadian province of QUEBEC in  2003 
in 1189 patients showed  median delay of reperfusion 
therapy was 32 minutes in patients receiving 
fibrinolytic therapy.22 Evaluation of door to needle 
time in a tertiary care hospital, in India in 2015 showed 
73 percent of patients failed to receive thrombolytic 
therapy within 30 minutes.23 Similar study done in 58 
Urban Emergency departments in U.S. comprised of 
3,819 patients who presented between 2003 and 2006, 
showed low to moderate concordance with guideline-
recommended processes of care for patients of AMI.24 
A data from Punjab Institute of Cardiology  Lahore 
showed door-to-needle time of more than 30min in 
46.2% patients.25 Similar studies done in India, Saudi 
Arabia and Vancouver showed that ACCA 
recommendation of door to needle time is not properly 
followed.26,27,28,31 
In Benazir Bhutto Hospital, the mean door to needle 
time as per present study is 44.8 min. Only 28.7% 
patients received reperfusion therapy within 30min of 
arrival in ER .So, a large proportion of patients did not 
receive fibrinolytic therapy in time. Factors that 
contributed to the increase of door to needle time 
were, inappropriate referral of cardiac patients to the 
medical units by the triage personnel, delay in the 
acquisition of ECG, delay in interpretation of ECG as 
its interpretation and the decision to thrombolyse are 
reliable in more experienced doctors than junior 
doctor,  patients presenting with atypical symptoms, 
non-availability of thrombolytics in the cardiac bay 
and   delay in acquisition of thrombolytics from the 
emergency administration due to administrative 
issues.. 29These factors significantly increase door to 
needle time and can be addressed by application of  
different pre-emptive and emergency measures , e.g., 
early ECG acquisition for at-risk patients, emergency 
staff training, the presence of a senior 
doctor/physician on the floor or being readily 
available, better co-ordination between hospital 
administration, emergency staff and physicians, 
improve auxiliary services to enhance patient flow, the 
ready availability of fibrinolytic medicine in the 
cardiac bay.Most quality improvement studies suggest 
a team-based approach to improving the time-to-
reperfusion therapy for MI patients.22,24,30  
A Study in Armed Forces Institute of Cardiology , 
Rawalpindi showed  that more than 70% of the 
patients were thrombolysed within 30 mins of arrival 
i.e. door to needle time <30 minutes.32 In hospital 
associated with Andhra Medical College, 
Visakhapatnam, Andhra Pradesh, India, they have 
been able to reduce the door to needle time for 
intravenous thrombolysis to about ten minutes by 
ensuring the presentation of a patient, with chest pain, 
directly to  ICCU without going through the 
emergency room / outpatient registration.This 
revealed efficient hospital organisational strategy to 
handle cardiac patients.33Similarly doctors at a rural 
district general hospital in New Zealand conducted a 
research, which revealed that introducing a number of 
simple low-cost interventions that included 
educational sessions for junior doctors and cardiac 
nursing staff, as well as posters and training on the use 
of a remote electronic ECG interpretation system to 
streamline out-of-hours  management, they have been 
able to achieve recommended door to needle time in 
74 percent of patients as compared to 43 percent 
without these interventions.34  
Conclusion 
A significant number of patients were not 
thrombolysed within 30 minutes of presentation 
(71.3%).The lack of senior doctors, difficulty 
interpreting ECGs, atypical presentations and EC 
system delays prolonged the door-to-needle time in 
this study. 
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